Tamibarotene for the Treatment of Bronchiolitis Obliterans Associated With Chronic Graft-vs-Host Disease.
Allografts
Benzoates
/ therapeutic use
Biopsy
Bronchiolitis Obliterans
/ diagnosis
Chronic Disease
Follow-Up Studies
Graft vs Host Disease
/ complications
Hematopoietic Stem Cell Transplantation
/ adverse effects
Humans
Leukemia, Promyelocytic, Acute
/ therapy
Lung
/ diagnostic imaging
Male
Middle Aged
Tetrahydronaphthalenes
/ therapeutic use
Tomography, X-Ray Computed
bronchiolitis obliterans
graft-vs-host disease
tamibarotene
Journal
Chest
ISSN: 1931-3543
Titre abrégé: Chest
Pays: United States
ID NLM: 0231335
Informations de publication
Date de publication:
01 2019
01 2019
Historique:
received:
18
05
2018
revised:
16
07
2018
accepted:
01
08
2018
entrez:
9
1
2019
pubmed:
9
1
2019
medline:
12
10
2019
Statut:
ppublish
Résumé
Bronchiolitis obliterans (BO) is a significant life-threatening complication that occurs after allogeneic hematopoietic stem cell transplantation (allo-HSCT), and it is associated with increased morbidity and mortality. BO responds poorly to corticosteroids or immunosuppressants, and there are currently no established treatment approaches. We herein describe a patient with biopsy-proven BO after allo-HSCT who was successfully treated with tamibarotene, a novel synthetic retinobenzoic acid. Tamibarotene led to a dramatic improvement in lung function as well as cutaneous manifestations of chronic graft-vs-host disease. A large prospective clinical trial is therefore warranted to confirm the efficacy of tamibarotene in BO.
Identifiants
pubmed: 30616741
pii: S0012-3692(18)32340-7
doi: 10.1016/j.chest.2018.08.1052
pii:
doi:
Substances chimiques
Benzoates
0
Tetrahydronaphthalenes
0
tamibarotene
08V52GZ3H9
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e1-e4Informations de copyright
Copyright © 2018 American College of Chest Physicians. Published by Elsevier Inc. All rights reserved.